2 citations,
July 2023 in “JAAD Case Reports” A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
[object Object] 4 citations,
January 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
January 2016 in “Chemistry & Industry” Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
50 citations,
May 2021 in “Frontiers in immunology” Certain immune cells contribute to skin autoimmune diseases, and some treatments can reverse hair loss in these conditions.
Different scalp and hair disorders are more common in certain ethnic groups, with the most common being androgenetic alopecia, which is treated with medications like minoxidil and finasteride.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
1 citations,
February 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
20 citations,
January 2017 in “Actas Dermo-Sifiliográficas” Recent advances in hair loss treatments show significant progress.
November 2023 in “Aktualʹnì problemi sučasnoï medicini” The guidelines suggest using various treatments, including antidepressants and steroids, for alopecia areata and discuss the condition's genetic and immune aspects.
August 2023 in “Journal of The American Academy of Dermatology” Early treatment is key for permanent hair loss disorders, with options ranging from medications and phototherapy to immunomodulators and antibiotics, depending on severity and type.
October 2020 in “Revista médica sinergía/Revista médica sinergia” Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.
January 2019 in “Springer eBooks” Combination therapies might work better for some vitiligo patients, but results vary.
December 2023 in “European journal of dermatology/EJD. European journal of dermatology” More effective treatments are needed for severe alopecia areata.
January 2023 in “The Egyptian Journal of Hospital Medicine” New treatments for sudden hair loss include oral medications and a special laser, both showing promise in hair regrowth.
3 citations,
March 2021 in “Clinical, Cosmetic and Investigational Dermatology” Early treatment of Lupus Erythematosus Alopecia can prevent permanent hair loss, and various medications are effective.
December 2023 in “JEADV Clinical Practice” A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.
Hair loss can be caused by hormones, illness, autoimmune disorders, or vitamin deficiencies, and treatments vary depending on the type.
Baricitinib may effectively treat oral lichen planus.
56 citations,
January 2019 in “Lancet” JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
11 citations,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
[object Object] 9 citations,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
63 citations,
April 2018 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help treat some skin conditions but need more research.
4 citations,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
3 citations,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
1 citations,
November 2017 in “Dermatologic therapy” JAK inhibitors show promise as a future treatment for hair loss.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
37 citations,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.